BRAVO PHARMA (UK) LTD - Limited company accounts 18.2

REGISTERED NUMBER: 10493421 (England and Wales)

REPORT OF THE DIRECTORS AND

UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 23 NOVEMBER 2016 TO 30 NOVEMBER 2017

FOR

BRAVO PHARMA (UK) LTD

Page

Company Information

1

Report of the Directors

2

Income Statement

3

Balance Sheet

4

Notes to the Financial Statements

5

DIRECTORS:

K K Patel

R Pandey

SECRETARY:

N Patel

REGISTERED OFFICE:

Unit 1, Conqueror Court

Spilsby Road

Harold Hill

Romford

Essex

RM3 8SB

REGISTERED NUMBER:

10493421 (England and Wales)

ACCOUNTANTS:

Kiew Consulting

Suite 100A

Airport House

Croydon

Surrey

CR0 0XZ

The directors present their report with the financial statements of the company for the period 23 November 2016 to 30 November 2017.

INCORPORATION

The company was incorporated on 23 November 2016 .

DIRECTORS

The directors who have held office during the period from 23 November 2016 to the date of this report are as follows:

K K Patel - appointed 23 November 2016

R Pandey - appointed 23 November 2016

Both the directors who are eligible offer themselves for election at the forthcoming first Annual General Meeting.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

K K Patel - Director

22 August 2018

TURNOVER

-

Administrative expenses

4,809

OPERATING LOSS and

LOSS BEFORE TAXATION

(4,809

)

Tax on loss

-

LOSS FOR THE FINANCIAL PERIOD

(4,809

)

FIXED ASSETS

Tangible assets

5

1,754

CURRENT ASSETS

Debtors

6

50

Cash at bank

1,737

1,787

CREDITORS

Amounts falling due within one year

7

3,300

NET CURRENT LIABILITIES

(1,513

)

TOTAL ASSETS LESS CURRENT
LIABILITIES

241

CAPITAL AND RESERVES

Called up share capital

100

Share premium

4,950

Retained earnings

(4,809

)

241

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 30 November 2017.

The members have not required the company to obtain an audit of its financial statements for the period ended 30 November 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each
financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395
and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as
applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 22 August 2018 and were signed on its behalf by:

K K Patel - Director

1.	STATUTORY INFORMATION

BRAVO PHARMA (UK) LTD is a private company, limited by shares , registered in England and Wales. The company's

registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings

-

25% on reducing balance

Computer equipment

-

25% on reducing balance

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent

that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively

enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet

date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in

which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been

enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be

recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL.

4.	OPERATING LOSS

The operating loss is stated after charging:

£

Depreciation - owned assets

584

5.	TANGIBLE FIXED ASSETS

Fixtures

and

Computer

fittings

equipment

Totals

£

COST

Additions

1,584

754

2,338

At 30 November 2017

1,584

754

2,338

DEPRECIATION

Charge for period

396

188

584

At 30 November 2017

396

188

584

NET BOOK VALUE

At 30 November 2017

1,188

566

1,754

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Other debtors

50

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Other creditors

3,300